The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus infection – the first update since 2012 – during a special session at its International Liver Congress last month in Amsterdam. For the first time, the guidelines include tenofovir alafenamide and present evidence about when and how to stop antiviral therapy.
Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination being developed by Merck, researchers reported at the International Liver Congress.
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the International Liver Congress.
Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported at the International Liver Congress.
AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus, the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the International Liver Congress.
A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side-effects, Xavier Forns reported on behalf of the EXPEDITION-1 study investigators at the International Liver Congress.
People with hepatitis C who take treatment with direct-acting antivirals do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the International Liver Congress.
England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland and the Netherlands are the least restrictive, research presented at the International Liver Congress shows.
Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented at the International Liver Congress shows.